These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 36520261)

  • 21. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes.
    Masuda H; Brewer TM; Liu DD; Iwamoto T; Shen Y; Hsu L; Willey JS; Gonzalez-Angulo AM; Chavez-MacGregor M; Fouad TM; Woodward WA; Reuben JM; Valero V; Alvarez RH; Hortobagyi GN; Ueno NT
    Ann Oncol; 2014 Feb; 25(2):384-91. PubMed ID: 24351399
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pathology of triple negative breast cancer.
    Borri F; Granaglia A
    Semin Cancer Biol; 2021 Jul; 72():136-145. PubMed ID: 32544511
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunological therapy: A novel thriving area for triple-negative breast cancer treatment.
    Wang X; Qi Y; Kong X; Zhai J; Li Y; Song Y; Wang J; Feng X; Fang Y
    Cancer Lett; 2019 Feb; 442():409-428. PubMed ID: 30419345
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Evolution of Triple-Negative Breast Cancer: From Biology to Novel Therapeutics.
    Anders CK; Abramson V; Tan T; Dent R
    Am Soc Clin Oncol Educ Book; 2016; 35():34-42. PubMed ID: 27249684
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of tumor-infiltrating lymphocytes in triple-negative breast cancer and the research progress of adoptive cell therapy.
    Li R; Cao L
    Front Immunol; 2023; 14():1194020. PubMed ID: 37275874
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recent Advances in Immunotherapy for Breast Cancer: A Review.
    Wen QE; Li L; Feng RQ; Li DH; Qiao C; Xu XS; Zhang YJ
    Breast Cancer (Dove Med Press); 2024; 16():497-516. PubMed ID: 39220564
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunotherapy in Combination with Chemotherapy for Triple-negative Breast Cancer.
    Elizabeth MS; Cristina SBJ; Christian CG
    Mini Rev Med Chem; 2024; 24(4):431-439. PubMed ID: 37198990
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunotherapy for Triple-Negative Breast Cancer: Latest Research and Clinical Prospects.
    Ahmed RF; Jameel F; Irfan M
    Crit Rev Immunol; 2019; 39(3):211-221. PubMed ID: 32421965
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunotherapy in triple-negative breast cancer.
    Katz H; Alsharedi M
    Med Oncol; 2017 Dec; 35(1):13. PubMed ID: 29255938
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Calycosin inhibits triple-negative breast cancer progression through down-regulation of the novel estrogen receptor-α splice variant ER-α30-mediated PI3K/AKT signaling pathway.
    Li Y; Hu S; Chen Y; Zhang X; Gao H; Tian J; Chen J
    Phytomedicine; 2023 Sep; 118():154924. PubMed ID: 37393829
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunotherapy for HER2-positive breast cancer: recent advances and combination therapeutic approaches.
    Ayoub NM; Al-Shami KM; Yaghan RJ
    Breast Cancer (Dove Med Press); 2019; 11():53-69. PubMed ID: 30697064
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.
    Maeda T; Nakanishi Y; Hirotani Y; Fuchinoue F; Enomoto K; Sakurai K; Amano S; Nemoto N
    Med Mol Morphol; 2016 Mar; 49(1):11-21. PubMed ID: 26009308
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Integrating Immunotherapy Into the Treatment Landscape for Patients With Triple-Negative Breast Cancer.
    Dixon-Douglas J; Loibl S; Denkert C; Telli M; Loi S
    Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-13. PubMed ID: 35649211
    [TBL] [Abstract][Full Text] [Related]  

  • 34. STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review.
    Qin JJ; Yan L; Zhang J; Zhang WD
    J Exp Clin Cancer Res; 2019 May; 38(1):195. PubMed ID: 31088482
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recent advances of transcriptomics and proteomics in triple-negative breast cancer prognosis assessment.
    Li Y; Kong X; Wang Z; Xuan L
    J Cell Mol Med; 2022 Mar; 26(5):1351-1362. PubMed ID: 35150062
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Research advances and new challenges in overcoming triple-negative breast cancer.
    Zong Y; Pegram M
    Cancer Drug Resist; 2021; 4(3):517-542. PubMed ID: 34888495
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic Significance of Single Progesterone Receptor Positivity: A Comparison Study of Estrogen Receptor Negative/Progesterone Receptor Positive/Her2 Negative Primary Breast Cancer With Triple Negative Breast Cancer.
    Fan Y; Ding X; Xu B; Ma F; Yuan P; Wang J; Zhang P; Li Q; Luo Y
    Medicine (Baltimore); 2015 Nov; 94(46):e2066. PubMed ID: 26579819
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunotherapy in triple-negative breast cancer: Insights into tumor immune landscape and therapeutic opportunities.
    Ribeiro R; Carvalho MJ; Goncalves J; Moreira JN
    Front Mol Biosci; 2022; 9():903065. PubMed ID: 36060249
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Distribution of molecular breast cancer subtypes among Algerian women and correlation with clinical and tumor characteristics: a population-based study.
    Cherbal F; Gaceb H; Mehemmai C; Saiah I; Bakour R; Rouis AO; Boualga K; Benbrahim W; Mahfouf H
    Breast Dis; 2015; 35(2):95-102. PubMed ID: 25736840
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recent Progress in Triple Negative Breast Cancer Research.
    Mouh FZ; Mzibri ME; Slaoui M; Amrani M
    Asian Pac J Cancer Prev; 2016; 17(4):1595-608. PubMed ID: 27221827
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.